Health
VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms – TCTMD
Whether the benefit-risk balance is favorable depends on many factors, but it will be so “in very many cases,” the researcher says.
Venous thromboembolic (VTE) events are indeed increased after people get the COVID-19 vaccine from Oxford/AstraZeneca, but the absolute risk is low considering the proven effectiveness of vaccination and the continued spread of SARS-CoV-2 around the globe, researchers report in the BMJ.
After vaccination programs got underway, spontaneous reports of thrombotic events in people who had received the vaccine started coming in, with several European countries pausing its use in March due to the clots….
-
Business17 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
General8 hours agoVictorian school teacher charged with soliciting child abuse material
-
Business19 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
General16 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips